Roche
FREE Daily Email Newsletter
Hospital to Probe East German Medical Trials
May 13, 2013 3:44 pm | by FRANK JORDANS,Associated Press | News | CommentsBerlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
Roche and Ascletis to Collaborate on Hepatitis C Treatment Options in China
April 15, 2013 8:21 am | News | CommentsRoche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche’s investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). It is estimated that over 10 million patients in China are chronically infected with HCV. The majority of these are genotype 1b, which has proven highly responsive to danoprevir.
Severe US Flu Season Helped Roche's Q1 Sales
April 11, 2013 7:53 am | by JOHN HEILPRIN,Associated Press | News | CommentsStrong sales of new cancer drugs and a severe U.S. flu season helped lift first-quarter revenue at Swiss drugmaker Roche Holding AG by 6 percent. The world's biggest manufacturer of cancer drugs said that sales rose to 11.56 billion Swiss francs ($12.4 billion) during the first three months of the year, up from 11.03 billion francs in the same period last year.
Drugmakers, Interpol Ramp Up Fight Against Fakes
March 12, 2013 1:01 am | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | CommentsMore than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
Galapagos and Roche Conclude Strategic Alliance
March 8, 2013 8:00 am | News | CommentsGalapagos NV announced today that it agreed with Roche to end their alliance in fibrosis. Roche will make a payment of EUR5.75 million to Galapagos for work completed in 2012, contributing to 2012 Group revenues. With the ending of the alliance, Galapagos has regained the worldwide rights to all fibrosis assays and the targets discovered in the alliance.
Humer to Step Down as Chairman of Roche
March 5, 2013 7:56 am | News | CommentsSwiss drugmaker Roche Holding AG says its chairman, Franz Humer, will step down next year after 13 years. The 66-year-old Humer announced at the company's annual general meeting Tuesday that he won't stand for re-election to the board in 2014. The company said it will nominate a successor this fall.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey
March 4, 2013 7:59 am | News | CommentsMore than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
FDA Approves New Targeted Breast Cancer Drug
February 25, 2013 8:11 am | by MATTHEW PERRONE,AP Health Writer | News | CommentsThe Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together.
Roche and Chiasma Announce Collaboration to Develop and Commercialize Chiasma's Octreolin for Acromegaly and Neuroendocrine Tumors
February 19, 2013 8:03 am | News | CommentsRoche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection.
FDA Warns of New Fake Batch of Cancer Drug Avastin
February 7, 2013 8:19 am | News | CommentsThe Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year. The FDA said in an online post Tuesday that at least one batch of the drug distributed by a New York company does not contain the active ingredient in real Avastin.
Roche launches new SeqCap EZ Reagent Kits to maximize customer convenience
January 30, 2013 4:22 am | by Roche | News | CommentsRoche announced today the global launch and availability of a new comprehensive suite of SeqCap EZ Reagent kits for application in single or multiplex target enrichment experiments prior to DNA Sequencing.
2013 Facility of the Year Awards (FOYA) Winners Announced
January 29, 2013 6:31 am | News | CommentsThe Facility of the Year Awards Judging Panel has named six Category Award Winners in the 2013 Facility of the Year Awards (FOYA) program. The winning projects for 2013 were selected from 27 well-qualified entries.
FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
January 24, 2013 2:58 am | News | CommentsGenentech, a member of the Roche Group has announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin ® (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).
Roche expands IT solutions array for the professional laboratory
January 21, 2013 1:23 am | by Roche | News | Commentscobas IT middleware enables the total automated laboratory. Roche enhances its lineup of IT solutions for the professional medical laboratory and today unveils cobas IT middleware, a software suite for fully automated workflow management. Enabling laboratory managers to easily link...
Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platforms
December 23, 2012 6:22 pm | by Roche | News | CommentsRoche and Precision System Science, Co., Ltd (PSS) today announced the signing of an exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument for Roche’s portfolio of next-generation sequencing platforms. It is intended to support Roche’s GS...
Roche & #039;s rapid mycoplasma detection test MycoTOOL receives FDA acceptance for release testing of biopharmaceutical Roche product
December 19, 2012 6:23 pm | by Roche | News | CommentsFirst commercially available mycoplasma PCR test accepted by FDA reduces time for detection from one month to one day. Today Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the use of its PCR based mycoplasma detection test MycoTOOL for release testing of one...
Roche 454 Sequencing Systems successfully resolve genetic mutations in over 4,000 blood cancer cases
December 11, 2012 3:22 am | by Roche | News | CommentsInternational study presented at American Society of Hematology Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions. At the American Society of Hematology Meeting (ASH)...
Roche's Zelboraf Named Best New Drug at the 2012 Scrip Awards
November 29, 2012 11:22 pm | by Roche | News | CommentsRoche announced today that its cancer drug Zelboraf (vemurafenib) won the Best New Drug award at the 2012 Scrip Awards ceremony held in London last night.
Roche introduces new GS FLX+ software for significantly improved long-read sequencing performance
November 14, 2012 5:23 pm | by Roche | News | CommentsRoche announced today the launch and immediate availability of a new software package (v2.8) that significantly improves long-read shotgun sequencing performance on its GS FLX+ System.
Roche and Agilent Technologies Establish Agreement to Provide Continued Service and Support to Roche NimbleGen Microarray Customers
November 14, 2012 5:23 pm | by Roche | News | CommentsRoche and Agilent Technologies, Inc. today announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases-out its NimbleGen array production and services.
Roche launches additional test for improved management of epithelial ovarian cancer patients in the U.S.
November 14, 2012 5:23 pm | by Roche | News | CommentsRoche announced today the U.S. market availability of the Elecsys HE4 assay, an FDA approved test used in monitoring patients with ovarian cancer. The HE4 test is used as an aid in monitoring the recurrence or progressive disease in patients with epithelial ovarian cancer.
British Medical Journal Slams Roche on Tamiflu
November 12, 2012 3:07 am | by MARIA CHENG,AP Medical Writer | News | CommentsLONDON (AP) — A leading British medical journal is asking the drug maker Roche to release all its data on Tamiflu, claiming there is no evidence the drug can actually stop the flu.
Roche launches new tools for RNA isolation and cDNA pre-amplification from FFPET samples
October 31, 2012 5:23 am | by Roche | News | CommentsToday Roche announced the global launch of its new High Pure FFPET RNA Isolation Kit as well as the RealTime ready cDNA Pre-Amp Master & Primer Pools. Formalin-fixed, paraffin-embedded tissue (FFPET) samples from biopsies or micro-dissections are frequently used for retrospective...
Roche launches new Cedex Bio HT Analyzer for cell fermentation process analytics
October 29, 2012 5:23 am | by Roche | News | CommentsToday Roche announced the global launch of its Cedex Bio HT Analyzer for the highly reliable determination of metabolites and substrates in mammalian and microbial cell fermentation. The Cedex Bio HT System offers very precise analytics, a broad test portfolio allowing flexible adaption...
Roche Investigated For Not Reporting Side Effects
October 23, 2012 3:55 am | by Associated Press | News | CommentsThe European Medicines Agency has started an infringement procedure against pharmaceutical giant Roche for allegedly failing to properly report side effects in patients in the U.S.
